This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Stromyer ML , Southerland MR , Satyal U , Sikder RK , Weader DJ , Baughman JA , Youngs WJ , Abbosh PH
Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines
Eur J Med Chem. 2020 Jan 1;185 :111832
PMID: 31718944 PMCID: PMC7224591 URL: https://www.ncbi.nlm.nih.gov/pubmed/31718944
AbstractImidazolium salts have shown great promise as anticancer materials. A new imidazolium salt (TPP1), with a triphenylphosphonium substituent, has been synthesized and evaluated for in vitro and in vivo cytotoxicity against bladder cancer. TPP1 was determined to have a GI50 ranging from 200 to 250muM over a period of 1h and the ability to effectively inhibit bladder cancer. TPP1 induces apoptosis, and it appears to act as a direct mitochondrial toxin. TPP1 was applied intravesically to a bladder cancer mouse model based on the carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN). Cancer selectivity of TPP1 was demonstrated, as BBN-induced tumors exhibited apoptosis but normal adjacent urothelium did not. These results suggest that TPP1 may be a promising intravesical agent for the treatment of bladder cancer.
Notes1768-3254 Stromyer, Michael L Southerland, Marie R Satyal, Uttam Sikder, Rahmat K Weader, David J Baughman, Jessi A Youngs, Wiley J Abbosh, Philip H Journal Article France Eur J Med Chem. 2020 Jan 1;185:111832. doi: 10.1016/j.ejmech.2019.111832. Epub 2019 Oct 31.